Albany, NY -- (SBWIRE) -- 01/24/2019 -- Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027

Market size of Pulmonary Arterial Hypertension was USD 4,360.23 Million in 2016 in 7MM

1. Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension, which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from right side of heart through lungs.
2. Idiopathic Pulmonary Arterial Hypertension is the most common type of Pulmonary Arterial Hypertension.
3. The disease is found to be more common among women as compared to men.

(Albany, US) DelveInsight launched a new report on Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027

Request for sample pages

Key topics covered
1. The report provides an in-depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends.
2. The report provides insights about the historical and current patient pool and forecasted trend for 7 major markets.
3. The report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs.
4. The market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

"Pulmonary Arterial Hypertension is classified as Idiopathic PAH, Heritable PAH, Drug/Toxin Induced PAH and PAH associated with conditions such as Connective Tissue Disease (CTD-PAH), Human Immunodeficiency Virus (HIV-PAH), Portopulmonary Hypertension and Congenital Heart Disease (CHD)-PAH on the basis of the cause of the underlying disease pathogenesis."

Despite the advancement in the diagnostic technique, its diagnosis is delayed among the patients. Its prevalence is increasing with an increase in geriatric population and change in lifestyle. Over the last decade, advancement in understanding of the pathogenesis and pathobiology of Pulmonary Arterial Hypertension has led to the development of therapies that have improved the symptoms of Pulmonary Arterial Hypertension.
Endothelin receptor antagonists and Rising demand of Prostanoids will fuel the PAH market. DelveInsight believes that the emerging Prostanoid therapies shall show remarkable growth in the coming years and have the potential to become the Standard of Care. Uptravi is expected to be the blockbuster drug with high sales in upcoming years. Increased use of double and triple combination therapies and patient assistance programs by manufacturers shall further impact the market size.

Companies covered
1. Actelion Pharmaceuticals Ltd.
2. United Therapeutics Corp.
3. Arena Pharmaceuticals
And many others

Drugs covered
1. Aurora-GT
2. Opsumit
3. Ralinepag
And many others

Table of contents

1. Report Introduction
2. Pulmonary Arterial Hypertension Market Overview at a Glance
2.1. Global Market Share(%) Distribution of Pulmonary Arterial Hypertension in 2017
2.2. Global Market Share (%) Distribution of Pulmonary Arterial Hypertension in 2027
3. Pulmonary Arterial Hypertension (PAH): Overview
3.1. Signs and Symptoms
3.2. Classification of Pulmonary Arterial Hypertension (PAH)
3.3. Functional Classification of PAH
3.4. Etiology
3.5. Risk factors
3.6. Pathophysiology
3.7. Diagnosis
3.8. Treatment
4. Epidemiology and Patient Population
4.1. Key Points
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Pulmonary Arterial Hypertension (PAH) in 7MM
5. Pulmonary Arterial Hypertension (PAH): Country- Wise Epidemiology
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Treatment Algorithm
7. Unmet Needs
8. Marketed Drugs
8.1. Approval and Market Presence
8.2. Marketed Drugs by Companies
8.2.1. United Therapeutics Corporation
8.2.2. Actelion Pharmaceuticals Ltd.
8.2.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
8.2.4. Bayer AG
8.2.5. Pfizer
8.3. Safety and Efficacy of Marketed Drugs
9. Emerging Therapies
9.1. Key Cross Competition
9.2. Aurora-GT: United Therapeutics
9.3. Macitentan: Actelion Pharmaceuticals
9.4. Ralinepag: Arena Pharmaceuticals
9.5. LIQ861: Liquidia Technologies
10. Global Market Outlook: Pulmonary Arterial Hypertension (PAH)
11. Global Market Size of Pulmonary Arterial Hypertension (PAH)
12. 7MM: PAH Country-Wise Market Analysis
12.1. United States
12.2. EU5
12.3. Rest of Europe (ROE)
12.4. Japan
12.5. Rest of World (ROW)
13. Market Drivers
14. Market Barriers
15. Appendix
16. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight